Compare STTK & CAAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | STTK | CAAS |
|---|---|---|
| Founded | 2016 | N/A |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Auto Parts:O.E.M. |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 119.0M | 123.7M |
| IPO Year | 2020 | N/A |
| Metric | STTK | CAAS |
|---|---|---|
| Price | $3.05 | $4.37 |
| Analyst Decision | Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $4.00 | N/A |
| AVG Volume (30 Days) | ★ 392.9K | 24.8K |
| Earning Date | 11-06-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 5.68 |
| EPS | N/A | ★ 1.11 |
| Revenue | $1,000,000.00 | ★ $725,260,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $3.89 |
| Revenue Growth | N/A | ★ 16.72 |
| 52 Week Low | $0.69 | $3.50 |
| 52 Week High | $3.38 | $5.37 |
| Indicator | STTK | CAAS |
|---|---|---|
| Relative Strength Index (RSI) | 67.21 | 55.85 |
| Support Level | $2.82 | $4.06 |
| Resistance Level | $3.30 | $4.43 |
| Average True Range (ATR) | 0.24 | 0.15 |
| MACD | -0.00 | 0.03 |
| Stochastic Oscillator | 74.76 | 71.11 |
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.
China Automotive Systems Inc is a holding company. The firm through its subsidiary is a supplier of power steering systems and components to China's automotive industry. Its product offering encompasses a full range of auto parts incorporated into steering systems for both passenger automobiles and commercial vehicles. The company offers four separate series, models of power steering including rack and pinion power steering, integral power steering, electronic power steering and manual steering, steering columns, steering oil pumps, and steering hoses. Geographically, it derives a majority of its revenue from China.